DBF20 Antibody

What is DBF20 and why is it important in cell cycle research?

DBF20 is a cell cycle-regulated protein kinase in budding yeast Saccharomyces cerevisiae that functions similarly to its paralog DBF2 in controlling late mitotic events and the telophase/G1 transition. DBF20 has significant relevance in cell cycle studies because it operates within a conserved signaling pathway known as the Mitotic Exit Network (MEN). Understanding DBF20 function provides insights into fundamental mechanisms of cell division and its dysregulation in pathological conditions .

The protein interacts with regulatory factors such as MOB1, forming complexes that are essential for proper cell cycle progression. Research has demonstrated that while a single deletion of either DBF2 or DBF20 is viable, a dbf2 dbf20 double deletion is lethal, indicating partially redundant but collectively essential functions .

What are the primary applications for DBF20 antibodies in research?

DBF20 antibodies serve multiple crucial research applications:

• Protein detection and quantification: Western blotting to identify DBF20 expression levels across different cell types or experimental conditions

• Protein-protein interaction studies: Immunoprecipitation experiments to isolate DBF20 complexes with binding partners like MOB1

• Localization studies: Immunofluorescence microscopy to determine the subcellular distribution of DBF20 during different cell cycle phases

• Chromatin immunoprecipitation: Investigating potential roles in transcriptional regulation

• Flow cytometry: Analyzing DBF20 expression in individual cells within heterogeneous populations

Selection of the appropriate application depends on your specific research question and experimental system .

How does DBF20 antibody specificity differ from DBF2 antibody specificity?

Due to the high sequence similarity between DBF2 and DBF20 (paralogs with overlapping functions), antibody specificity is a critical consideration. The specificity differences are typically determined by:

• Epitope selection: High-quality DBF20-specific antibodies target unique amino acid sequences not present in DBF2, particularly within the non-conserved regions of the proteins

• Validation methods: Cross-reactivity testing using knockout controls (e.g., dbf20Δ and dbf2Δ strains) is essential to confirm specificity

• Binding characteristics: DBF20 antibodies may demonstrate different affinity and avidity profiles compared to DBF2 antibodies

Researchers should verify antibody specificity through multiple validation approaches, particularly when studying systems where both proteins are expressed .

What are the recommended protocols for using DBF20 antibody in Western blotting?

For optimal Western blot results with DBF20 antibody:

• Sample preparation:

  • For yeast samples: Use glass bead lysis in buffer containing 50 mM HEPES pH 7.6, 150 mM KCl, 1 mM EDTA, 10% glycerol, and protease inhibitors

  • Include phosphatase inhibitors (1 mM sodium pyrophosphate, 1 mM NaF) to preserve phosphorylation states

• Electrophoresis and transfer:

  • Use 10% SDS-PAGE gels for optimal resolution of DBF20 (predicted MW: ~62 kDa)

  • Transfer to PVDF membrane at 100V for 1 hour or 30V overnight

• Antibody incubation:

  • Block membrane with 5% non-fat dry milk in TBST for 1 hour

  • Incubate with primary DBF20 antibody at 1:1000 dilution (typically 1 μg/mL) overnight at 4°C

  • Use HRP-conjugated secondary antibody at 1:5000 dilution for 1 hour at room temperature

• Detection and analysis:

  • Develop using enhanced chemiluminescence reagents

  • DBF20 typically appears as a band at approximately 62-65 kDa

  • Expression levels may vary with cell cycle phases and should be normalized to appropriate loading controls

How should I optimize immunoprecipitation experiments when studying DBF20 protein-protein interactions?

Optimizing immunoprecipitation (IP) for DBF20 protein-protein interaction studies requires:

• Lysis buffer selection:

  • Use a buffer containing 50 mM HEPES (pH 7.6), 150 mM KCl, 1% Nonidet P-40, 10% glycerol, 5 mM MgCl₂, 1 mM EDTA plus protease inhibitors

  • Include phosphatase inhibitors (1 mM sodium pyrophosphate, 1 mM NaF) to preserve signaling events

• Antibody coupling:

  • Pre-couple 20 mg Protein A-agarose with 0.02-0.03 mg of DBF20 antibody for 30-60 minutes

  • Wash antibody-coupled beads once with lysis buffer before adding lysate

• IP conditions:

  • Use 700 μg of total protein per IP reaction

  • Incubate lysates with antibody-coupled beads at 4°C for 60 minutes

  • Perform at least two washes with lysis buffer after IP

• Co-IP detection:

  • For known interactions (e.g., DBF20-MOB1), include specific antibodies against predicted binding partners

  • Consider crosslinking approaches for transient interactions

  • For novel interaction discovery, combine with mass spectrometry analysis

What controls should be included when validating a new lot of DBF20 antibody?

Proper validation of a new DBF20 antibody lot requires these essential controls:

Each control should be run under identical conditions to the experimental samples, with quantitative assessment of signal-to-noise ratios to determine antibody performance metrics .

How can I validate the specificity of a DBF20 antibody using genetic approaches?

Genetic validation strategies for DBF20 antibody specificity include:

• Knockout/knockdown validation:

  • Generate a dbf20Δ knockout strain or use RNAi to knockdown DBF20 expression

  • Compare antibody signal between wild-type and knockout/knockdown samples by Western blot

  • A specific antibody will show diminished or absent signal in knockout/knockdown samples

• Overexpression validation:

  • Construct a plasmid for DBF20 overexpression (e.g., using pRS305-DBF20)

  • Compare antibody signal between control and overexpressing samples

  • A specific antibody will show enhanced signal proportional to expression level

• Tag-based validation:

  • Create a strain expressing epitope-tagged DBF20 (e.g., HA- or Myc-tagged)

  • Perform parallel detection with both DBF20 antibody and tag-specific antibody

  • Signal co-localization confirms specific recognition of DBF20

See Figure 1 for an example of genetic validation using RNAi knockdown approach as demonstrated with other antibodies:

![Figure 1: Example of genetic validation by RNAi knockdown showing Western blot analysis of control and target-specific siRNA samples]

What orthogonal validation methods can complement traditional antibody validation approaches?

Orthogonal validation provides independent confirmation of DBF20 antibody specificity through complementary techniques:

• RNA-Seq correlation:

  • Compare DBF20 protein levels detected by antibody with mRNA expression data

  • Positive correlation supports antibody specificity (protein levels should generally follow transcript abundance patterns)

• Mass spectrometry validation:

  • Perform immunoprecipitation using the DBF20 antibody

  • Analyze precipitated proteins by mass spectrometry

  • Confirmation of DBF20 peptides as the predominant species validates specificity

• Multiple antibody concordance:

  • Test multiple antibodies targeting different DBF20 epitopes

  • Consistent detection patterns across antibodies supports specificity

• Functional assay validation:

  • Correlate antibody detection with known functional outcomes of DBF20 activity

  • For example, measure cell cycle progression effects when DBF20 is manipulated and correlate with antibody signal

How can I determine if my DBF20 antibody is suitable for immunohistochemistry or immunofluorescence applications?

Determining suitability for immunohistochemistry (IHC) or immunofluorescence (IF) requires systematic evaluation:

• Fixation optimization:

  • Test multiple fixation methods (paraformaldehyde, methanol, acetone)

  • Optimize fixation duration and temperature

  • DBF20 epitopes may be sensitive to specific fixation conditions

• Antibody titration:

  • Test serial dilutions (typically starting at 10 μg/mL and diluting 2-5 fold)

  • Determine optimal concentration that maximizes specific signal while minimizing background

• Antigen retrieval assessment:

  • Evaluate need for epitope unmasking (heat-induced or enzymatic methods)

  • Compare staining patterns with and without retrieval steps

• Specificity controls:

  • Include genetic controls (knockout/knockdown tissues)

  • Perform peptide competition assays

  • Include secondary-only controls to assess non-specific binding

• Subcellular localization confirmation:

  • Verify that staining pattern matches known DBF20 localization

  • For yeast, DBF20 typically shows cell cycle-dependent localization patterns

  • Co-staining with markers of specific cellular compartments can confirm proper localization

How can I use DBF20 antibody for studying protein-protein interactions in the Mitotic Exit Network?

To investigate DBF20's role in the Mitotic Exit Network (MEN) using antibody-based approaches:

• Co-immunoprecipitation network analysis:

  • Use DBF20 antibody to pull down protein complexes

  • Analyze interacting partners by Western blot with antibodies against known MEN components (MOB1, TEM1, CDC15)

  • Quantify interaction intensities under different cell cycle conditions

• Proximity ligation assays (PLA):

  • Utilize DBF20 antibody with antibodies against potential binding partners

  • PLA signals indicate close proximity (<40 nm) between proteins

  • Quantify interaction dynamics throughout cell cycle progression

• ChIP-seq approaches:

  • If DBF20 has chromatin association, use DBF20 antibody for ChIP-seq

  • Map binding sites genome-wide to identify potential transcriptional roles

  • Correlate binding patterns with cell cycle phases

• Microscopy-based interaction studies:

  • Combine DBF20 immunofluorescence with fluorescently tagged MEN components

  • Perform FRET analysis to detect direct protein interactions

  • Track co-localization dynamics during mitotic exit

What are the most common causes of non-specific binding when using DBF20 antibody, and how can they be mitigated?

Common causes of non-specific binding and their mitigation strategies include:

When non-specific binding persists, consider affinity purification of the antibody against the specific antigen or using alternative detection techniques .

How can DBF20 antibody be used in multiplexed imaging or flow cytometry applications?

For multiplexed detection involving DBF20 antibody:

• Panel design considerations:

  • Select fluorophores with minimal spectral overlap

  • Include appropriate compensation controls

  • Use sequential staining for antibodies with potential cross-reactivity

• Fixation and permeabilization optimization:

  • Test compatibility of fixation protocols with all antibodies in panel

  • Optimize permeabilization to maintain epitope accessibility while preserving cellular architecture

• Validation for multiplexed applications:

  • Test each antibody individually before combining

  • Perform fluorescence-minus-one (FMO) controls

  • Validate staining patterns match single-antibody results

• Analysis approaches:

  • Use dimensionality reduction techniques (tSNE, UMAP) for high-parameter data

  • Apply clustering algorithms to identify cell populations

  • Correlate DBF20 expression with cell cycle markers

What considerations are important when developing recombinant DBF20 antibodies for research applications?

When developing recombinant DBF20 antibodies, consider these key factors:

• Sequencing strategy:

  • Use a template-switch RT-PCR approach for antibody variable region amplification

  • Perform three separate reactions (kappa, lambda, and heavy chain transcripts)

  • Prime reverse transcription with constant region-specific primers

  • Use a template-switch oligonucleotide to create a custom sequence at the 5' end of the antibody cDNA

• Expression system selection:

  • Choose between bacterial (E. coli), mammalian (CHO, HEK293), or alternative expression systems

  • Consider post-translational modifications required for proper folding and function

  • Evaluate yield requirements and downstream applications

• Domain engineering:

  • Design chimeric constructs combining mouse variable regions with human constant regions

  • Consider Fc engineering to modify effector functions or half-life

  • Evaluate different isotypes based on application needs

• Validation approach:

  • Confirm binding specificity to recombinant DBF20 protein

  • Compare performance with original hybridoma-derived antibody

  • Assess batch-to-batch consistency through quality control metrics

• Stability considerations:

  • Optimize formulation to maintain activity during storage

  • Evaluate freeze-thaw stability

  • Consider lyophilization for long-term storage

How can DBF20 antibodies be used to investigate cell cycle regulation in yeast models?

DBF20 antibodies offer several approaches to study cell cycle regulation in yeast:

• Cell cycle-dependent phosphorylation:

  • Monitor DBF20 phosphorylation status across synchronized cell populations

  • Compare Western blot migration patterns with and without phosphatase treatment

  • Use phospho-specific antibodies (if available) to track specific modification sites

• Protein abundance regulation:

  • Quantify DBF20 levels throughout cell cycle using immunoblotting

  • Correlate protein levels with known cell cycle markers

  • Investigate protein degradation dynamics during mitotic exit

• Localization dynamics:

  • Track DBF20 subcellular distribution during cell cycle progression

  • Correlate localization changes with functional outcomes

  • Investigate co-localization with other MEN components

• Genetic interaction studies:

  • Combine antibody-based protein detection with genetic manipulations

  • Assess how mutations in interacting proteins affect DBF20 levels, modification, or localization

  • Study synthetic genetic interactions between DBF20 and other cell cycle regulators

What are the cutting-edge applications of using DNA-encoded monoclonal antibody technology for DBF20 research?

DNA-encoded monoclonal antibody (DMAb) technology represents an innovative approach that could be applied to DBF20 research:

• In vivo antibody production:

  • Unlike conventional antibodies manufactured externally, DMAbs are produced inside the organism

  • DNA instructions encoding DBF20-specific antibodies can be administered to organisms

  • The organism's cells translate these instructions to produce functional anti-DBF20 antibodies

• Research applications:

  • Functional inhibition studies: DMAbs can be designed to block specific DBF20 domains

  • Long-term expression: Persistent antibody production without repeated administration

  • Tissue-specific targeting: Restrict antibody production to specific cell types using tissue-specific promoters

• Technical considerations:

  • Delivery systems: Optimize DNA delivery using methods like electroporation

  • Expression optimization: Codon optimization for the target organism

  • Validation: Compare with conventional antibody approaches for consistency

• Potential advantages:

  • Reduced immunogenicity in long-term studies

  • Cost-effectiveness for extended experiments

  • Ability to express in difficult-to-reach tissues or compartments

How do different growth media conditions affect antibody quality in production systems?

Culture medium composition significantly impacts antibody quality through various mechanisms:

• Glycosylation profile effects:
  The table below shows how different commercial growth media affect glycoform distribution in a model antibody:

  Glycan Type	Medium A	Medium B	Medium C	Medium D
  High Mannose	2.4%	8.1%	5.3%	1.9%
  G0F	35.7%	41.3%	38.9%	37.2%
  G1F	47.5%	39.2%	42.8%	45.3%
  G2F	14.4%	11.4%	13.0%	15.6%
  Aglycosylation	1.8%	5.2%	3.1%	2.1%

• Principal component analysis:

  • Over 90% of variability in antibody glycosylation profiles can be characterized by two principal components

  • Medium selection has predictable effects on glycoform distribution

  • Models with high Q² values (>0.6) have strong predictive power for glycosylation outcomes

• Optimization strategies:

  • Target specific glycoform distributions by selecting appropriate media

  • Supplement with specific components to enhance desired modifications

  • Monitor batch-to-batch consistency through multivariate data analysis

• Functional implications:

  • Glycosylation patterns directly impact antibody effector functions

  • Aglycosylation levels affect antibody stability and half-life

  • G0F/G1F/G2F ratios influence complement activation and Fc receptor binding

This comprehensive understanding of medium effects is applicable to optimizing production of DBF20 antibodies with consistent quality and desired functional characteristics.